Novo Nordisk vows to sue after Hims & Hers launches Wegovy knockoff pill
Shares in Indianapolis-based Eli Lilly and Co., a rival to Novo Nordisk in the weight-loss market, also fell after the announcement, dropping 7.8% Thursday.
Eli Lilly and Co.
-
Lilly, IU sign clinical trial, research agreement worth up to $40M
Officials say the pact, facilitated by the Indianapolis-based IU Launch Accelerator for Biosciences, is the largest single industry-sponsored agreement in the school’s history.
Read More -
Lilly, Nvidia team up to build pharma’s ‘most powerful’ supercomputer
The Indianapolis-based drugmaker said the supercomputer will power an “AI factory” designed to accelerate drug discovery and development.
Read More -
Q&A with the head of Lilly manufacturing, who meticulously tracks gains in work, life
“People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of management.”
Read More -
Eli Lilly to spend $27B on four new manufacturing sites
The new manufacturing sites are expected to create create 3,000 pharmaceutical jobs and nearly 10,000 construction positions during the buildout.
Read More
Articles
Trump administration to launch TrumpRx website for discounted drugs
The president first teased TrumpRx in September while announcing the first of his more than 15 deals with pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., to lower drug prices.
Lilly earnings continue upward path on growth of Zepbound, Mounjaro
Eli Lilly and Co. shares soared in midday trading Wednesday after the drugmaker reported fourth-quarter results that topped Wall Street expectations.
Trump draws attention to Lilly’s massive building spree. Here’s what’s in the works.
Eli Lilly and Co. has announced $50 billion in U.S. expansion commitments since 2020, including numerous manufacturing plants all over the country.
Lilly to build $3.5B plant in Pennsylvania in 4th of 4 big U.S. investments
The new facility, part of a $27 billion reshoring investment, will produce the drugmaker’s weight-loss therapies.
Lilly signs $1.12B deal with Germany-based firm to develop hearing loss treatments
The agreement with Seamless is the latest in a series of purchases and partnerships Lilly has established to build a pipeline of genetic medicines.
Lilly receives FDA’s breakthrough therapy designation for ovarian cancer drug
Ovarian cancer is the fifth-leading cause of cancer death among women in the United States.
Popular weight-loss drugs shouldn’t carry suicide warnings, FDA says
U.S. Food and Drug Administration officials say a comprehensive review “found no increased risk” related to suicide among users of the GLP-1 drugs, including Eli Lilly and Co.’s Zepbound, used to treat obesity.
Lilly, Nvidia to establish $1B AI co-innovation lab in San Francisco
The new initiative expands on the massive artificial intelligence supercomputer collaboration the companies announced last fall.
Former GLP-1 users regain lost weight after about 18 months, study says
People who stop taking GLP-1 drugs such as Ozempic, Wegovy and Zepbound for weight loss are projected to regain their shed pounds within about 1-½ years, a review of existing research has found.
Lilly to acquire California-based biopharma company in $1.2B deal
Indianapolis-based Eli Lilly and Co. announced Wednesday it intends to acquire Ventyx Biosciences, a clinical-stage biopharmaceutical company developing oral therapies for inflammatory-mediated diseases.
Lilly in talks to buy Ventyx Biosciences for more than $1B, WSJ reports
Ventyx is a San Diego-based biotech that specializes in drugs for inflammatory diseases like Crohn’s and rheumatoid arthritis.
Eli Lilly set to back Aktis Oncology’s upsized $318M IPO
Clinical-stage biotechnology company Aktis Oncology increased the size of its initial public offering by 50% and drew interest from Indianapolis-based Lilly for $100 million of shares in the listing.
First GLP-1 weight-loss pill now available, with pledge of abundant supply
Novo Nordisk is aiming to avoid losing ground to its main rival, Eli Lilly, which is seeking regulatory approval for its own GLP-1 weight-loss pill.
Partnership between public affairs firms highlights growing Indiana-Ireland bond
A former Hoosier lawmaker and a former Irish government minister are linking their firms as Indiana’s ties to Ireland grow.
Indiana attorney general sues Lilly over insulin prices
Attorney General Todd Rokita said the lawsuit, filed last Wednesday in the Lake County Superior Court, is part of his office’s intensifying efforts to lower insulin prices and improve health care affordability.
2025 Newsmaker: David Ricks
As of Nov. 13, Eli Lilly and Co.’s market capitalization was $967 billion and flirting with a rare $1 trillion. Its stock price in November surpassed $1,000 per share, up more than 25% for the year.
US regulators approve Wegovy pill for weight loss, giving Novo Nordisk an edge over Lilly
Novo Nordisk’s Wegovy pills are expected to be available within weeks, while Indianapolis-based Eli Lilly and Co. waits for approval for its daily GLP-1 pill, orforglipron.
Lilly’s growth explosion tests state’s workforce development
Eli Lilly and Co.’s career website this month listed 254 job openings in Indianapolis and another 90 in Lebanon, accounting for more than three-quarters of the 445 open positions the pharmaceutical giant listed across the United States.
Lilly Phase 3 trial shows GLP-1 pill effective for weight-loss maintenance
According to the study, orforglipron users maintained their weight loss levels more closely after previously taking a rival’s GLP-1 injectable, the Indianapolis-based drugmaker said.